(Q36543057)

English

Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases

scientific article published on August 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases (English)

1 reference

Europe PubMed Central

14 August 2017

neurodegeneration

1 reference

based on heuristic

inferred from title

Moussa B. H. Youdim

4

object named as

Moussa B H Youdim

1 reference

Europe PubMed Central

14 August 2017

2

object named as

Shunit Gal

1 reference

Europe PubMed Central

14 August 2017

Cornelis J Van der Schyf

1

object named as

Cornelis J Van der Schyf

1 reference

Europe PubMed Central

14 August 2017

author name string

Werner J Geldenhuys

3

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

1 August 2006

1 reference

Europe PubMed Central

14 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

14 August 2017

15

1 reference

Europe PubMed Central

14 August 2017

8

1 reference

Europe PubMed Central

14 August 2017

873-886

1 reference

Europe PubMed Central

14 August 2017

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

From magic bullets to designed multiple ligands

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Combination therapy in Alzheimer's disease: a review of current evidence

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Designed multiple ligands. An emerging drug discovery paradigm

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Combination therapy of long-acting beta2-adrenoceptor agonists and corticosteroids for asthma.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Multicomponent therapeutics for networked systems

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibiti

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

The efficiency of multi-target drugs: the network approach might help drug design

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Is Transduced into Cellular Responses in Neurons: Ca2+Signals and Neurotransmitter Release

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

The cholinergic hypothesis of Alzheimer's disease: a review of progress

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Mechanisms of action of cognitive enhancers on neuroreceptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Modulation of the neuronal nicotinic acetylcholine receptor-channel by the nootropic drug nefiracetam.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Presynaptic nicotinic acetylcholine receptors as a functional target of nefiracetam in inducing a long-lasting facilitation of hippocampal neurotransmission

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

NMDA receptor pathways as drug targets

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Synthesis, biological evaluation and molecular modelling of diversely functionalized heterocyclic derivatives as inhibitors of acetylcholinesterase/butyrylcholinesterase and modulators of Ca2+ channels and nicotinic receptors.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

ITH4012 (ethyl 5-amino-6,7,8,9-tetrahydro-2-methyl-4-phenylbenzol[1,8]naphthyridine-3-carboxylate), a novel acetylcholinesterase inhibitor with "calcium promotor" and neuroprotective properties

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

The role of dihydropyridine-sensitive voltage-gated calcium channels in potassium-mediated neuronal survival.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Iron, brain ageing and neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Iron metabolism and the IRE/IRP regulatory system: an update

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Iron regulatory proteins and the molecular control of mammalian iron metabolism

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Metal and inflammatory targets for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Apomorphine protects against MPTP-induced neurotoxicity in mice.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

New developments in iron chelators

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Monoamine oxidase-B inhibition in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Recent developments in the drug treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Does caffeine intake protect from Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Caffeine as a neuroprotective adenosine receptor antagonist

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Stroke and cognition.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Animal models of stroke: do they have value for discovering neuroprotective agents?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion: adverse effects of hypothalamic damage and strategies for its avoidance

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Neuronal protective effects of calcium antagonists in cerebral ischemia.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Evaluation of memantine for neuroprotection in dementia

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Rational drug design and the discovery of the delta2-1,2,3-triazolines, a unique class of anticonvulsant and antiischemic agents

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Effects of homocysteine on the dopaminergic system and behavior in rodents

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Homocysteine, cerebrovascular disease and brain atrophy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Body weight influences pharmacokinetics of levodopa in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Levodopa in plasma correlates with body weight of parkinsonian patients

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Diagnostic staging of Parkinson's disease: conceptual aspects

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Practical importance of neuroprotection in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.8.873

21 January 2018

Identifiers

10.1517/13543784.15.8.873

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36543057&oldid=2161418282"